MT110-101, NCT00635596: Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer |
|
|
| Completed | 1 | 65 | Europe | MT110, bispecific T-cell engager (BiTE) | Amgen Research (Munich) GmbH | Solid Tumors | 01/14 | 01/15 | | |
